Threshold Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference

(firmenpresse) - REDWOOD CITY, CA -- (Marketwire) -- 09/02/11 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present at the Stifel Nicolaus Healthcare Conference in Boston on Friday, September 9, 2011 at 8:35AM EDT.

A Live webcast of the presentation will be available under the Webcast section of the Company's Website.



Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ().



Joel A. Fernandes
Threshold Pharmaceuticals, Inc.
650.474.8273

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 02.09.2011 - 12:30 Uhr
Sprache: Deutsch
News-ID 61937
Anzahl Zeichen: 0

contact information:
Town:

REDWOOD CITY, CA

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 256 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Threshold Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Threshold Pharmaceuticals (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms ...

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/11/16 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for t ...

Threshold Pharmaceuticals Announces Workforce Reduction ...

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/18/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the nea ...

Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfam ...

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/07/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an invest ...

Alle Meldungen von Threshold Pharmaceuticals